Literature DB >> 4004142

[Hepatic metastases of breast cancer. Analysis of the parameters which influence the response to chemotherapy].

P Pouillart, M Jouvet, T Palangie, E Garcia-Giralt, B Bretaudeau, T Dorval, B Asselain.   

Abstract

In a serie of 759 patients treated for metastasized cancer of the breast, presence of an hepatic focus was observed in 29 percent of cases. Isolated hepatic metastases were found in 4 percent of cases while in 25 percent they were associated with other tissues. At the time of initial clinical staging, the difference between the hepatic metastases group and the other group stems from the much greater frequency of severity indices in the former group indicating a general and biological transformation of the metastatic tumor(s). At therapeutic staging, the slight effectiveness of medical therapies can be accounted for by the slight tolerance among patients with a secondary hepatic tumor(s). Lastly, it is interesting to note that progesterone receptor presence does not modify the prognosis in hepatic metastases cases.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4004142

Source DB:  PubMed          Journal:  Ann Gastroenterol Hepatol (Paris)        ISSN: 0066-2070


  3 in total

1.  Rapid extravasation and establishment of breast cancer micrometastases in the liver microenvironment.

Authors:  Michelle D Martin; Gert-Jan Kremers; Kurt W Short; Jonathan V Rocheleau; Lei Xu; David W Piston; Lynn M Matrisian; D Lee Gorden
Journal:  Mol Cancer Res       Date:  2010-08-19       Impact factor: 5.852

2.  Treatment outcome of patients with liver-only metastases from breast cancer after mastectomy: a retrospective analysis.

Authors:  Xiao Feng Duan; Na Na Dong; Ti Zhang; Qiang Li
Journal:  J Cancer Res Clin Oncol       Date:  2011-07-26       Impact factor: 4.553

3.  Liver resection for breast cancer metastasis: does it improve survival?

Authors:  Jean Lubrano; Horace Roman; Sophie Tarrab; Benoit Resch; Loïc Marpeau; Michel Scotté
Journal:  Surg Today       Date:  2008-03-27       Impact factor: 2.549

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.